{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:29:04Z","timestamp":1788020944967,"version":"build-2784847793"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013826","name":"Candys Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The real-world use of triptans in the treatment of migraine is disappointing. Only 12% of the Danish migraine population purchased a triptan between 2014 and 2019, and only 43% repurchased a triptan after first prescription. The aim of the present study was to assess whether physicians and patients adhere to the therapeutic guideline on acute migraine treatment. We interviewed 299 triptan experienced participants with migraine and 101 triptan na\u00efve participants with migraine from the Danish Migraine Population Cohort, using a semi-structured questionnaire. Descriptive statistical analyses were used to study the association with triptan use and the assessed factors. Among triptan na\u00efve participants with migraine, 64% had consulted their general practitioner about their migraine, of whom only 23% received information about the possibility of triptan treatment. Among triptan experienced participants, 77% had only tried one type of triptan. Only 12% could recall they had been informed by their general practitioner to try each triptan three times before giving up. Twenty percent were informed to try three different triptans in total, if the first did not work. In disagreement with the guideline, participants who reported a low pain reduction by a triptan had only tried one type of triptan. Our study shows a low adherence to therapeutic guideline for the attack treatment of migraine. There is a need for better education of general practitioners regarding treatment of migraine. Future campaigns should aim to inform both the public and the general practitioner about antimigraine treatments.<\/jats:p>","DOI":"10.1038\/s41598-022-12545-2","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T16:05:03Z","timestamp":1652976303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Low adherence to the guideline for the acute treatment of migraine"],"prefix":"10.1038","volume":"12","author":[{"given":"Astrid","family":"Olesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Winther","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisse Rye","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Topholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaspar","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Erikstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Birger","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Folkmann","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Ameri","family":"Chalmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"12545_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421991809","author":"OB Davidsson","year":"2021","unstructured":"Davidsson, O. B. et al. Twenty-five years of triptans\u2014a nationwide population study. Cephalalgia https:\/\/doi.org\/10.1177\/0333102421991809 (2021).","journal-title":"Cephalalgia"},{"key":"12545_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01228-4","volume":"22","author":"HW Schytz","year":"2021","unstructured":"Schytz, H. W. et al. Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020. J. Headache Pain 22, 1\u201331. https:\/\/doi.org\/10.1186\/s10194-021-01228-4 (2021).","journal-title":"J. Headache Pain"},{"key":"12545_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14737175.2021.1842733","volume":"21","author":"E Mart\u00ednez-P\u00edas","year":"2021","unstructured":"Mart\u00ednez-P\u00edas, E. et al. Triptanophobia in migraine: A case-control study on the causes and consequences of the nonuse of triptans in chronic migraine patients. Expert Rev. Neurother. 21, 123\u2013130. https:\/\/doi.org\/10.1080\/14737175.2021.1842733 (2021).","journal-title":"Expert Rev. Neurother."},{"key":"12545_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava, Z. et al. Poor medical care for people with migraine in Europe\u2014Evidence from the Eurolight study. J. Headache Pain 19, 10. https:\/\/doi.org\/10.1186\/s10194-018-0839-1 (2018).","journal-title":"J. Headache Pain"},{"key":"12545_CR5","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2015-1-19-26","author":"ER Lebedeva","year":"2015","unstructured":"Lebedeva, E. R., Kobzeva, N. R., Gilev, D. V. & Olesen, E. Analysis of the quality of diagnosis and treatment of primary headache in different social groups of the ural region. Neurol. Neuropsychiatry Psychosom. https:\/\/doi.org\/10.14412\/2074-2711-2015-1-19-26 (2015).","journal-title":"Neurol. Neuropsychiatry Psychosom."},{"key":"12545_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/s0317167100017819","volume":"40","author":"I Worthington","year":"2013","unstructured":"Worthington, I. et al. Canadian headache society guideline: Acute drug therapy for migraine headache. Can. J. Neurol. Sci. 40, S1\u2013S80. https:\/\/doi.org\/10.1017\/s0317167100017819 (2013).","journal-title":"Can. J. Neurol. Sci."},{"key":"12545_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14656566.2020.1828347","volume":"22","author":"P Tfelt-Hansen","year":"2021","unstructured":"Tfelt-Hansen, P. Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opin. Pharmacother. 22, 305\u2013316. https:\/\/doi.org\/10.1080\/14656566.2020.1828347 (2021).","journal-title":"Expert Opin. Pharmacother."},{"key":"12545_CR8","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4031580","author":"MA Chalmer","year":"2022","unstructured":"Chalmer, M. A. et al. Reappraisal of sex differences in migraine. SSRN Electron. J. https:\/\/doi.org\/10.2139\/ssrn.4031580 (2022).","journal-title":"SSRN Electron. J."},{"key":"12545_CR9","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38,1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202 (2018)","DOI":"10.1177\/0333102417738202"},{"key":"12545_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0333102419877171","volume":"40","author":"MA Chalmer","year":"2019","unstructured":"Chalmer, M. A. et al. Proposed new diagnostic criteria for chronic migraine. Cephalalgia 40, 399\u2013406. https:\/\/doi.org\/10.1177\/0333102419877171 (2019).","journal-title":"Cephalalgia"},{"key":"12545_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/0333102413508661","volume":"34","author":"K Thorlund","year":"2014","unstructured":"Thorlund, K. et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia 34, 258\u2013267. https:\/\/doi.org\/10.1177\/0333102413508661 (2014).","journal-title":"Cephalalgia"},{"key":"12545_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1526-4610.2003.03073.x","volume":"43","author":"G G\u00e9raud","year":"2003","unstructured":"G\u00e9raud, G., Keywood, C. & Senard, J. M. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 43, 376\u2013388. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03073.x (2003).","journal-title":"Headache"},{"key":"12545_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1468-2982.1994.1405330.x","volume":"14","author":"MD Ferrari","year":"1994","unstructured":"Ferrari, M. D. et al. Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 14, 330\u2013338. https:\/\/doi.org\/10.1046\/j.1468-2982.1994.1405330.x (1994).","journal-title":"Cephalalgia"},{"key":"12545_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/qjmed\/89.8.613","volume":"89","author":"RJ Scott","year":"1996","unstructured":"Scott, R. J., Aitchison, W. R. C., Barker, P. R. & McLaren, G. I. Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. QJM 89, 613\u2013622. https:\/\/doi.org\/10.1093\/qjmed\/89.8.613 (1996).","journal-title":"QJM"},{"key":"12545_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/pds.4723","volume":"28","author":"RW Thomsen","year":"2019","unstructured":"Thomsen, R. W. et al. Patterns of initial migraine treatment in Denmark: A population-based study. Pharmacoepidemiol. Drug Saf. 28, 322\u2013329. https:\/\/doi.org\/10.1002\/pds.4723 (2019).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"12545_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby, P. J., Lipton, R. B. & Ferrari, M. D. Migraine\u2014current understanding and treatment. N. Engl. J. Med. 346, 257\u2013270. https:\/\/doi.org\/10.1056\/NEJMra010917 (2002).","journal-title":"N. Engl. J. Med."},{"key":"12545_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009108.pub2","author":"CJ Derry","year":"2014","unstructured":"Derry, C. J., Derry, S. & Moore, R. A. Sumatriptan (all routes of administration) for acute migraine attacks in adults\u2014overview of Cochrane reviews. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD009108.pub2 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"12545_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/11630590-000000000-00000","volume":"26","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen, P. & Olesen, J. Taking the negative view of current migraine treatments: The unmet needs. CNS Drugs 26, 375\u2013382. https:\/\/doi.org\/10.2165\/11630590-000000000-00000 (2012).","journal-title":"CNS Drugs"},{"key":"12545_CR19","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/j.1526-4610.1999.00006.x","volume":"39","author":"RB Lipton","year":"1999","unstructured":"Lipton, R. B. & Stewart, W. F. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?. Headache J. Head Face Pain 39, S20\u2013S26. https:\/\/doi.org\/10.1111\/j.1526-4610.1999.00006.x (1999).","journal-title":"Headache J. Head Face Pain"},{"key":"12545_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari, M. D., Goadsby, P. J., Roon, K. I. & Lipton, R. B. Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22, 633\u2013658. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00404.x (2002).","journal-title":"Cephalalgia"},{"issue":"Suppl 2","key":"12545_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0333102499019s2505","volume":"19","author":"BK Rasmussen","year":"1999","unstructured":"Rasmussen, B. K. Epidemiology and socio-economic impact of headache. Cephalalgia 19(Suppl 2), 20\u201323. https:\/\/doi.org\/10.1177\/0333102499019s2505 (1999).","journal-title":"Cephalalgia"},{"key":"12545_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1423-0410.2011.01553.x","volume":"102","author":"OB Pedersen","year":"2012","unstructured":"Pedersen, O. B. et al. The Danish Blood Donor Study: A large, prospective cohort and biobank for medical research. Vox Sang 102, 271. https:\/\/doi.org\/10.1111\/j.1423-0410.2011.01553.x (2012).","journal-title":"Vox Sang"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12545-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12545-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:35:28Z","timestamp":1669347328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12545-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12545"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12545-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8487"}}